The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Destiny’s date with a partner
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
Another huge quarter in 2017 for biotech flotations
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.